246246-19-5
Chemical Structure
AL-8810
- CAS No.: 246246-19-5
- Formula:C24H31FO4
- Molecular Weight:402.50
IUPAC Name: (Z)-7-((1R,2R,3S,5S)-2-((R,E)-3-(2,3-dihydro-1H-inden-2-yl)-3-hydroxyprop-1-en-1-yl)-3-fluoro-5-hydroxycyclopentyl)hept-5-enoic acid
InChIKey: WTYSXBKKVNOOIX-JTGCGUAKSA-N
SMILES: O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](C2CC3=C(C=CC=C3)C2)O)[C@@H](F)C[C@@H]1O
Biological Activity: AL-8810 is a potent and selective antagonist of the PGF 2α receptor (FP receptor). AL-8810 is an activator of MAPK and ERK1/2. The Ki of the FP receptor of mouse 3T3 cells and rat A7r5 cells are 0.2±0.06 μM and 0.4±0.1 μM, respectively. AL-8810 can be used in the study of elevated intraocular pressure (OHT) and primary open-angle glaucoma (POAG)[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AL-8810 | 99.00% | AL-8810 is a potent and selective antagonist of the PGF 2α receptor (FP receptor). AL-8810 is an activator of MAPK and ERK1/2. The Ki of the FP receptor of mouse 3T3 cells and rat A7r5 cells are 0.2±0.06 μM and 0.4±0.1 μM, respectively. AL-8810 can be used in the study of elevated intraocular pressure (OHT) and primary open-angle glaucoma (POAG). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Griffin BW, et al. AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther. 1999 Sep;290(3):1278-84. [Content Brief]
- [2]. Kim YT, et al. Prostaglandin FP receptor inhibitor reduces ischemic brain damage and neurotoxicity. Neurobiol Dis. 2012 Oct;48(1):58-65. doi: 10.1016/j.nbd.2012.06.003. Epub 2012 Jun 16. [Content Brief]
- [3]. Goupil E, et al. Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK. Mol Endocrinol. 2012 Jul;26(7):1189-202. [Content Brief]
- [4]. Sharif NA, et al. Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility. Br J Pharmacol. 2019 Apr;176(8):1059-1078. [Content Brief]
- [5]. Glushakov AV, et al. Prostaglandin F2α FP receptor antagonist improves outcomes after experimental traumatic brain injury. J Neuroinflammation. 2013 Oct 30;10:132. [Content Brief]
